Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations.

Nature medicine - 1 Apr 1996

Howard M, Frizzell R A, Bedwell D M

Abstract excerpt

Cystic fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR). A single recessive mutation, the deletion of phenylalanine 508 (deltaF508), causes severe CF and resides on 70% of mutant chromosomes. Severe CF is also caused by premature stop mutations, which are found on 5% of CF chromosomes. Here we report that two common, disease-associated stop mutations can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CFTR gene

Share to Gentamicins

Share to HeLa Cells

Share to Mutation

Share to Suppression, Genetic

Source

Identifiers

PMID: 8597960
DOI: 10.1038/nm0496-467

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations.PMID 8597960Read ↗

Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line.Semantic proximity Read ↗

Pharmacologic therapy for stop mutations: how much CFTR activity is enough?Semantic proximity Read ↗

Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene.Semantic proximity Read ↗

Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.Semantic proximity Read ↗

No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.Semantic proximity Read ↗

Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse modelSemantic proximity Read ↗

Poly-l-aspartic Acid Enhances and Prolongs Gentamicin-mediated Suppression of the CFTR-G542X Mutation in a Cystic Fibrosis Mouse ModelSemantic proximity Read ↗

In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.Semantic proximity Read ↗

Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop MutationsSemantic proximity Read ↗

Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice.Semantic proximity Read ↗

Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by IvacaftorSemantic proximity Read ↗

A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.